These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 34749751)

  • 1. Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia.
    Sivkov A; Chernus N; Gorenkov R; Sivkov S; Sivkova S; Savina T
    Lipids Health Dis; 2021 Nov; 20(1):157. PubMed ID: 34749751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
    Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study.
    Zakria M; Hussain A; Ahmad N; Ahmed N; Rauf MA; Siraj S
    Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4708-4717. PubMed ID: 37259755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.
    Karlson BW; Wiklund O; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):212-7. PubMed ID: 27533947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment.
    Ruiz-Iruela C; Padró-Miquel A; Pintó-Sala X; Baena-Díez N; Caixàs-Pedragós A; Güell-Miró R; Navarro-Badal R; Jusmet-Miguel X; Calmarza P; Puzo-Foncilla JL; Alía-Ramos P; Candás-Estébanez B
    PLoS One; 2018; 13(10):e0205430. PubMed ID: 30304062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
    Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
    Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia.
    Hu M; Mak VW; Tomlinson B
    Pharmacogenet Genomics; 2012 Nov; 22(11):803-6. PubMed ID: 22668755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
    Voora D; Shah SH; Reed CR; Zhai J; Crosslin DR; Messer C; Salisbury BA; Ginsburg GS
    Circ Cardiovasc Genet; 2008 Dec; 1(2):100-6. PubMed ID: 20031551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
    Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
    Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Bharath G; Vishnuprabu DP; Preethi L; Nagappan AS; Dhianeshwaran Isravanya RT; Bhaskar LV; Swaminathan N; Munirajan AK
    Pharmacogenomics; 2022 Aug; 23(12):683-694. PubMed ID: 35968761
    [No Abstract]   [Full Text] [Related]  

  • 16. Periodic rosuvastatin or atorvastatin dosing arrays (PRADA): patient-centered practice.
    Christou T; Omar HR; Dimitrov R
    Drugs R D; 2014 Dec; 14(4):221-5. PubMed ID: 25160776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy.
    Lin J; Zhang Y; Zhou H; Wang X; Wang W
    Clin Lab; 2015; 61(9):1317-24. PubMed ID: 26554252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
    Milner E; Ainsworth M; Gleaton M; Bookstaver D
    J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
    Ramakumari N; Indumathi B; Katkam SK; Kutala VK
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.